RECRUITING

Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake, and 2) evaluate patient outcomes related to the effectiveness of MORE decreasing opioid, tobacco, and other drug use.

Official Title

Motivational Interviewing (MI) and Mindfulness-Oriented Recovery Enhancement (MORE) for Tobacco Dependence and Other Drug Use in Methadone Treatment

Quick Facts

Study Start:2023-09-05
Study Completion:2027-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06033599

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * English-speaking
  2. * Age ≥18
  3. * Currently on methadone; and 4) currently smoke cigarettes.
  1. * Severe cognitive impairment (score \>23 on Mini Mental Status Exam) or psychosis (positive SCID Psychotic Screen)
  2. * Suicidal risk (score ≥7 on Suicidal Behaviors Questionnaire)
  3. * Inability to attend or fully participate in intervention sessions or assessments
  4. * Previous formal mindfulness training (e.g., MBSR, MBRP) or MORE (from the R21 or R33
  5. * Currently taking smoking cessation pharmacotherapy or participating in smoking cessation counseling
  6. * Any contraindications for NRT
  7. * Currently or soon planning to be pregnant or breastfeeding.

Contacts and Locations

Study Contact

Nina Cooperman, PsyD
CONTACT
732-235-8569
cooperna@rwjms.rutgers.edu
Eric Garland, PhD
CONTACT
801-581-3826
eric.garland@socwk.utah.edu

Principal Investigator

Nina Cooperman, PsyD
PRINCIPAL_INVESTIGATOR
Rutgers Robert Wood Johnson Medical School

Study Locations (Sites)

Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08901
United States
University of Utah
Salt Lake City, Utah, 84108
United States

Collaborators and Investigators

Sponsor: Rutgers, The State University of New Jersey

  • Nina Cooperman, PsyD, PRINCIPAL_INVESTIGATOR, Rutgers Robert Wood Johnson Medical School

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-05
Study Completion Date2027-06-30

Study Record Updates

Study Start Date2023-09-05
Study Completion Date2027-06-30

Terms related to this study

Additional Relevant MeSH Terms

  • Polysubstance Abuse
  • Opioid Use
  • Tobacco Use